EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients

Noriko Ouji-Sageshima iD, Aiko Hiyama, Makiko Kumamoto, Masahiro Kitabatake, Atsushi Hara, Ryutaro Furukawa, Shigeto Hontsu, Takeshi Kawaguchi, Noriyoshi Sawabata iD, Shigeo Muro iD, Toshihiro Ito

Cells · 12.12.2024 · 13 (24) · 2050

DOI: 10.3390/cells13242050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 12.12.2024. Verfasst von Noriko Ouji-Sageshima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Nara Medical University, Kashihara 634-8521, Nara, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Mesenchymal Stem Cells, Fibroblasts, Lung. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, ROHTO Pharmaceutical Co., Ltd., JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is the most common type of fibrosis in lungs, characterized as a chronic and progressive interstitial lung disease involving pathological findings of fibrosis with a median survival of 3 years. Despite the knowledge accumulated regarding IPF from basic and clinical research, an effective medical therapy for the condition remains to be established. Thus, it is necessary for further research, including stem cell therapy, which will provide new insights into and expectations for IPF treatment. Recently, it has been reported that one of the new therapeutic candidates for IPF is adipose-derived mesenchymal stem cells (ADSCs), which have several benefits, such as easy accessibility and minimal morbidity compared to bone marrow-derived mesenchymal stem cells. Therefore, we investigated the possibility of ADSCs as a therapeutic candidate for IPF. Using human lung fibroblasts (LFs) from IPF patients, we demonstrated that human IPF LFs cocultured with ADSCs led to reduced fibrosis-related genes. Further analysis revealed that ADSCs prevented the activation of the ERK signaling pathway in IPF LFs via the upregulation of protein tyrosine phosphatase receptor-type R (PTPRR), which negatively regulates the ERK signaling pathway. Moreover, we demonstrated that intravascular administration of ADSCs improved the pathogenesis of bleomycin-induced pulmonary fibrosis with reduced collagen deposition in histology and hydroxyproline quantification and collagen markers such as the gene expression of types I and III collagen and α-smooth muscle actin (α-SMA) in a murine model. ADSC transfer was also investigated in a humanized mouse model of lung fibrosis induced via the infusion of human IPF LFs, because the bleomycin installation model does not fully recapitulate the pathogenesis of IPF. Using the humanized mouse model, we found that intravascular administration of ADSCs also improved fibrotic changes in the lungs. These findings suggest that ADSCs are a promising therapeutic candidate for IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisMesenchymal Stem CellsFibroblastsLungAdipose TissueHumansAnimalsMiceBleomycinMesenchymal Stem Cell TransplantationMaleMice, Inbred C57BLDisease Models, AnimalMAP Kinase Signaling System

Stichwörter der Autor:innen

ADSCIPFPTPRRcollagenhumanized mice

Substanzen

Bleomycin

Autor:innen und Institutionen

  • Department of Immunology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
  • Department of Respiratory Medicine, Nara Medical University, Kashihara 634-8521, Nara, Japan.
  • Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Kashihara 634-8521, Nara, Japan.

ORCID-Profile: Noriko Ouji-Sageshima, Noriyoshi Sawabata, Shigeo Muro

Förderung

  • Japan Society for the Promotion of Science
  • ROHTO Pharmaceutical Co., Ltd.
  • JSPS KAKENHI

Zitieren

APA

Ouji-Sageshima, N., Hiyama, A., Kumamoto, M., Kitabatake, M., Hara, A., Furukawa, R., Hontsu, S., Kawaguchi, T., Sawabata, N., Muro, S., & Ito, T. (2024). Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. Cells, 13(24), 2050. https://doi.org/10.3390/cells13242050

Vancouver

Ouji-Sageshima N, Hiyama A, Kumamoto M, Kitabatake M, Hara A, Furukawa R, et al. Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. Cells. 2024;13(24):2050. doi:10.3390/cells13242050

BibTeX
@article{OujiSageshima2024,
  author = {Ouji-Sageshima, Noriko and Hiyama, Aiko and Kumamoto, Makiko and Kitabatake, Masahiro and Hara, Atsushi and Furukawa, Ryutaro and Hontsu, Shigeto and Kawaguchi, Takeshi and Sawabata, Noriyoshi and Muro, Shigeo and Ito, Toshihiro},
  title = {Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {24},
  pages = {2050},
  doi = {10.3390/cells13242050}
}
Kostenlos starten →